Recent progress in conventional and biologic therapy for systemic lupus erythematosus.
The recent approval of belimumab for the treatment of systemic lupus erythematosus (SLE) ended a decade in which there was mounting optimism about the prospect for developing biologically based therapies for SLE. During this same period, steady progress had been made in understanding and applying conventional therapies for SLE. These advances in the use of conventional therapies provide an important frame of reference for evaluating the novel biologic therapies that are expected to emerge in the near future.